The FDA on November 6, 2017, granted regular approval to ZELBORAF® for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation. ZELBORAF® is a product of Hoffmann-La Roche Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement